Effective Immunochemotherapy for Aggressive Non-Hodgkin's Lymphoma

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 2, 2004, Pages 7-11

  Coiffier, Bertrand ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; AGE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 1542408996     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.003     Document Type: Conference Paper

References (24)

1. DeVita VT Jr, Canellos GP, Chabner B, et al: Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1:248-250, 1975
2. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
3. Linch DC, Vaughan Hudson B, Hancock BW, et al: A randomised comparison of a third-generation regimen (PACE-BOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: A British National Lymphoma Investigation report. Br J Cancer 74:318-322, 1996
4. Pfreundschuh M, Truemper L, Kloess M, et al: 2-weekly vs. 3-weekly CHOP with and without etoposide for patients > 60 years of age with aggressive non-Hodgkin's lymphoma (NHL): Results of the completed NHL-B-2 trial of the DSHNHL. Blood 100:774a, 2002a (abstr)
5. Pfreundschuh M, Truemper L, Schmits R, et al: 2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma: Results of the completed NHL-B-1 Trial of the DSHNHL. Blood 100:92a, 2002b (abstr)
6. Coiffier B, Gisselbrecht C, Herbrecht R, et al: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
7. Tilly H, Lepage E, Coiffier B, et al: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood 102:4284-4289, 2003
8. Tilly H, Mounier N, Lederlin P, et al: Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 18:1309-1315, 2000
9. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A Groupe d'Etudes des Lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000
10. Gisselbrecht C, Lepage E, Molina T, et al: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002
11. Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001
12. Vose JM, Link BK, Grossbard ML, et al: Long term follow-up of a phase 11 study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Blood 100:361a, 2002 (abstr)
13. Coiffier B, Lepage E, Herbrecht R, et al: MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial. Blood 96:223a, 2000 (abstr)
14. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
15. Coiffier B, Herbrecht R, Morel P, et al: GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Hematol J 4:111, 2003 (abstr)
16. Coiffier B, Lepage E, Gaulard P, et al: Prognostic factors affecting the efficacy of rituximab plus CHOP (R-CHOP) therapy in elderly patients with diffuse large B-cell lymphoma (DLCL): Results of a randomized GELA trial. Proc Am Soc Clin Oncol 20:283a, 2001 (abstr)
17. Ghielmini M, Hsu Schmitz S-F, Cogliatti S, et al: Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: A randomised SAKK trial. Blood 100:161a, 2002 (abstr)
18. Hainsworth JD, Litchy S, Burris HA III, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
19. Reed JC: Bcl-2 family proteins: Regulators of chemoresistance in cancer. Toxicol Lett 82-83:155-158, 1995
20. Hermine O, Haioun C, Lepage E, et al: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 87:265-272, 1996
21. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003
22. Jost LM, Jermann M, Stahel RA, et al: Rituximab-EPOCH - An effective salvage regime for relapsed, refractory, or transformed B-cell lymphoma. Results of a phase II study. Proc Am Soc Clin Oncol 20:290a, 2001 (abstr)
23. Kewalramani T, Zelenetz A, Bertino J, et al: Rituximab significantly increases the CR rate in patients with relapsed or primary refractory diffuse large B cell lymphoma receiving ICE as second line therapy. Blood 98:346a, 2001 (abstr)
24. Younes A, McLaughlin P, Hagemeister FB, et al: High response rate and complete remission rate achieved by adding rituximab to taxol plus topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B cell lymphoma. Blood 98:345a, 2001 (abstr)